EcoDrugPlus

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSOMYG00000045034
Gene Symbol: PSMC1
1 Cross references
87 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSOMYG00000021821
Gene Symbol: PSMC2
1 Cross references
231 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSOMYG00000008822
Gene Symbol: PSMC2
1 Cross references
231 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSOMYG00000016511
Gene Symbol: PSMC3
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSOMYG00000003914
Gene Symbol: PSMC4
1 Cross references
191 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSOMYG00000029658
Gene Symbol: PSMC4
1 Cross references
190 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSOMYG00000030586
Gene Symbol: PSMC6
1 Cross references
234 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSOMYG00000008540
Gene Symbol: PSMC6
1 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSOMYG00000061520
Gene Symbol: PSMD1
1 Cross references
208 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSOMYG00000000934
Gene Symbol: PSMD1
2 Cross references
208 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSOMYG00000032266
Gene Symbol: PSMD12
1 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSOMYG00000016336
Gene Symbol: PSMD12
1 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).